Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICX-TRC
- Development stage
- Phase 2
- Lead developer
- Intercytex
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
ICX-TRC is an autologous cell therapy developed for the treatment of hair loss and hair regeneration. The product is composed of dermal papilla (DP) cells, which are harvested from a small number of the patient's own hair follicles, expanded in vitro using a proprietary cell culture process, and then reinjected into the scalp. The therapeutic mechanism relies on the ability of these expanded DP cells to induce the formation of new hair follicles or to rejuvenate existing miniaturized follicles by signaling to the surrounding epithelial cells. Developed by the UK-based regenerative medicine company Intercytex, ICX-TRC reached Phase II clinical trials; however, development was discontinued following disappointing trial results and the company's subsequent financial difficulties.
- Other names
- Intercytex TRC
Beyond the preview
Go deeper on ICX-TRC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICX-TRC.